Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 December 2020
Prof Abdon Atangana
Prof Abdon Atangana is known for his work in developing a new fractional operator used to model real-world problems arising in the fields of science, technology, and engineering. He was recently awarded the TWAS Mohammad A. Hamdan Award by The World Academy of Sciences.

Prof Abdon Atangana, Professor of Applied Mathematics in the Institute for Groundwater Studies at the University of the Free State (UFS), was awarded the TWAS Mohammad A. Hamdan Award by The World Academy of Sciences for the advancement of science in developing countries.

It is the first time that the TWAS Mohammad A. Hamdan Award was bestowed. According to a statement issued by TWAS, this award is given for outstanding mathematical work carried out by a scientist working and living in Africa or the Arab region. It states that the award can be given for work in pure mathematics, applied mathematics, probability, or statistics. Prof Atangana received the award for his contribution to fractal mathematics and partial differential equations.

Making a difference in society

He is known for his research in developing a new fractional operator, the Atangana-Baleanu operator, which is used to model real-world problems. With this operator, he not only describes the rate at which something will change, but also account for disrupting factors that will help to produce better projections.

His work can be applied to make complicated predictions in the fields of science, technology, and engineering. His models can, for instance, help to predict the spread of infectious diseases among people in a settlement, forecasting the number of people who will be infected each day, the number of people who will recover, and the number of people who will die.

Prof Atangana’s models can also help to advise people drilling for water by predicting how groundwater is flowing in a complex geological formation. These are only two examples of how his work can be applied to make a difference in society.

The award from TWAS is the third prestigious commendation he has received in the past month. He was recently named as one of the top 1% scientists on the global Clarivate Web of Science list. His name also appeared on a global list of leading scientists published by Stanford University in the United States. The list is the result of a study published in PLOS Biology, a peer-reviewed open-access journal.

World’s most accomplished scientists

Honours awarded by TWAS and its partners are among the most prestigious for research in the developing world. They recognise outstanding achievements and contributions to science and acknowledge the best work by scientists from the global South.

TWAS, founded in 1983 by a group of scientists under the leadership of Pakistani physicist and Nobel laureate, Abdus Salam, believes that developing nations – by growing strength in science and engineering – will be able to address challenges such as hunger, disease, and poverty, through their knowledge and skills.

TWAS is represented in 100 countries, and of the more than a thousand elected fellows, 14 are Nobel laureates. Eighty-four percent of these fellows are from developing nations. TWAS fellows are also some of the world’s most accomplished scientists.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept